Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

G

G.V. (Sonny) Montgomery VA Medical Center

Status and phase

Unknown
Phase 1

Conditions

Infection
Herpesvirus 2, Human
Hepatitis C Virus Infection

Treatments

Drug: Valacyclovir

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT01037621
VAL R 152
2009-00348 (Other Identifier)

Details and patient eligibility

About

This trial is to determine the safety of valacyclovir in persons with chronic hepatitis C and herpes simplex type 2 infection. Participants will be randomized to valacyclovir or matching placebo. After receiving the initial therapy for eight weeks, the participants will cross over to the alternate therapy for an additional eight weeks. Each treatment period will be separated by a two-week period of daily placebo. The hypothesis is that treatment with valacyclovir will result in a significant reduction in serum levels of hepatitis C virus ribonucleic acid.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Clinical diagnosis of hepatitis C infection
  • Clinical diagnosis of herpes simplex type 2 infection

Exclusion criteria

  • HIV infection
  • Other forms of chronic liver disease
  • Chronic medical conditions
  • On immunosuppressive medications

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems